Clinical Trials
131
14 active
Approvals
4
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
11
8.4%
Completed
68
51.9%
Enrolling By Invitation
2
1.5%
Not yet recruiting
1
0.8%
Recruiting
7
5.3%
Suspended
1
0.8%
Terminated
33
25.2%
Withdrawn
8
6.1%
- Novartis reported that late-stage testing of its del-desiran drug for myotonic dystrophy failed to meet its primary endpoint, marking the company's second drug development setback in as many days. - The failure follows a closely watched setback announced Monday, when experimental cholesterol drug pelacarsen failed to deliver positive results in a late-stage trial. - Novartis shares tumbled sharply, falling 8.8% to 10.9% across European trading, and the news weighed on sentiment across the broader pharmaceutical sector. - The dual setbacks underscore the high-risk nature of late-stage clinical development for the Swiss drugmaker and pressured drugmaker stocks including AstraZeneca and Smith+Nephew.
- A new interdisciplinary German consensus published in *Die Chirurgie* offers the first risk-based, practical guidance for single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. - The consensus identifies sNPWT as a targeted preventive option for patients at increased risk of postoperative wound complications, including those with obesity, diabetes mellitus, smoking history, or prolonged surgical duration. - Clear treatment boundaries are defined, recommending sNPWT for wounds with an anticipated exudate volume of up to 300 ml per week to support differentiated clinical decision-making. - The guidance, supported by Smith+Nephew, highlights the PICO 7 sNPWT system's canister-free, portable design and AIRLOCK technology as facilitating evidence-based integration into inpatient and outpatient care pathways.
